Syngene International Ltd

The inspection concluded successfully, with the facility found to be in compliance with the required regulations. The inspection resulted in zero observations and no Form 483 was issued. The inspection has been classified as 'no action indicated' (NAI). 'The company remains commitment to high operating standards and rigorous compliance with global regulatory requirements across all its operations,' Syngene said in a statement. Syngene International is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. On a consolidated basis, net profit of Syngene International declined 2.81% to Rs 183.30 crore while net sales rose 11.03% to Rs 1018 crore in Q4 March 2025 over Q4 March 2024. The scrip had lost 1.57% to end at Rs 652.50 on the BSE on Friday. Powered by Capital Market - Live

On a consolidated basis, net profit of Syngene International declined 2.81% to Rs 183.30 crore while net sales rose 11.03% to Rs 1018 crore in Q4 March 2025 over Q4 March 2024. Reported EBITDA rose 9% year-on-year to Rs 363 crore in Q4 March 2025. EBITDA margin (%) stood at 35% in Q4FY25, lower than 35.7% in Q4FY24. For the full year, net profit declined 2.71% to Rs 496.20 crore while net sales rose 4.41% to Rs 3642.40 crore in the year ended March 2025 over the year ended March 2024. Reported EBITDA rose 1% year-on-year to Rs 1,114 crore in FY25. EBITDA margin (%) stood at 30% in FY25, lower than 30.9% in FY24. In its outlook for FY26, the Syngene management anticipates the reported revenue growth will likely be in the mid-single digits. They also foresee the EBITDA margin moderating from current levels to the mid-twenties and a year-on-year decline in profit after tax. Commenting on the results, Peter Bains, managing director and CEO, Syngene International, said, Looking at the year ahead, while the wider global market dynamics remain uncertain, we expect the business momentum to continue with pipeline build in both small and large molecules, supported by new pilot programs and conversion of existing pilots in discovery services. On an underlying basis for fiscal year 2026, we expect revenue growth in the early teens reflecting a broad-based growth across research, development and manufacturing services. Adjusted for inventory balancing in large molecule commercial manufacturing at client level, the reported revenue growth is likely to be at mid-single digit. Deepak Jain, chief financial officer, Syngene International, said, Looking ahead into the next financial year, we expect the momentum to continue, with reported revenue growth at the mid-single digit level. As we bring the new biologics manufacturing facilities into operations, the additional operating costs and depreciation will impact margins. With this, we expect EBITDA margin to moderate from current levels to the mid-twenties and year-on-year decline in profit after tax. The company's board recommended a final dividend of Re 1.25 per equity share for the financial year 2024-25. Syngene International is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Powered by Capital Market - Live

Nava Ltd, 360 ONE WAM Ltd, KFin Technologies Ltd and Can Fin Homes Ltd are among the other losers in the BSE's 'A' group today, 24 April 2025.Syngene International Ltd lost 13.07% to Rs 652 at 14:47 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 6.27 lakh shares were traded on the counter so far as against the average daily volumes of 16486 shares in the past one month.Nava Ltd tumbled 4.70% to Rs 470.05. The stock was the second biggest loser in 'A' group.On the BSE, 37641 shares were traded on the counter so far as against the average daily volumes of 34596 shares in the past one month.360 ONE WAM Ltd crashed 4.30% to Rs 1015.75. The stock was the third biggest loser in 'A' group.On the BSE, 62266 shares were traded on the counter so far as against the average daily volumes of 68845 shares in the past one month.KFin Technologies Ltd fell 4.26% to Rs 1231.55. The stock was the fourth biggest loser in 'A' group.On the BSE, 73027 shares were traded on the counter so far as against the average daily volumes of 1.36 lakh shares in the past one month.Can Fin Homes Ltd plummeted 4.26% to Rs 713. The stock was the fifth biggest loser in 'A' group.On the BSE, 39072 shares were traded on the counter so far as against the average daily volumes of 20594 shares in the past one month.Powered by Capital Market - Live

Natco Pharma Ltd, Newgen Software Technologies Ltd, MMTC Ltd, Glaxosmithkline Pharmaceuticals Ltd are among the other stocks to see a surge in volumes on NSE today, 24 April 2025.Syngene International Ltd registered volume of 168.31 lakh shares by 14:14 IST on NSE, a 34.31 fold spurt over two-week average daily volume of 4.91 lakh shares. The stock slipped 12.51% to Rs.655.45. Volumes stood at 6.35 lakh shares in the last session.Natco Pharma Ltd clocked volume of 144.27 lakh shares by 14:14 IST on NSE, a 34.05 times surge over two-week average daily volume of 4.24 lakh shares. The stock gained 8.94% to Rs.920.00. Volumes stood at 3.69 lakh shares in the last session.Newgen Software Technologies Ltd saw volume of 117.97 lakh shares by 14:14 IST on NSE, a 28.87 fold spurt over two-week average daily volume of 4.09 lakh shares. The stock increased 13.03% to Rs.1,122.60. Volumes stood at 14 lakh shares in the last session.MMTC Ltd registered volume of 410.32 lakh shares by 14:14 IST on NSE, a 26.01 fold spurt over two-week average daily volume of 15.78 lakh shares. The stock rose 14.15% to Rs.63.73. Volumes stood at 14.89 lakh shares in the last session.Glaxosmithkline Pharmaceuticals Ltd recorded volume of 17.98 lakh shares by 14:14 IST on NSE, a 14.9 times surge over two-week average daily volume of 1.21 lakh shares. The stock gained 3.19% to Rs.2,937.50. Volumes stood at 85241 shares in the last session.Powered by Capital Market - Live

Syngene International announced that the 32nd Annual General Meeting(AGM) of the company will be held on 23 July 2025.Powered by Capital Market - Live

Syngene International announced that the Board of Directors of the Company at its meeting held on 23 April 2025, inter alia, have recommended the final dividend of Rs 1.25 per equity Share (i.e. 12.5%) , subject to the approval of the shareholders.Powered by Capital Market - Live

Net profit of Syngene International declined 2.81% to Rs 183.30 crore in the quarter ended March 2025 as against Rs 188.60 crore during the previous quarter ended March 2024. Sales rose 11.03% to Rs 1018.00 crore in the quarter ended March 2025 as against Rs 916.90 crore during the previous quarter ended March 2024. For the full year,net profit declined 2.71% to Rs 496.20 crore in the year ended March 2025 as against Rs 510.00 crore during the previous year ended March 2024. Sales rose 4.41% to Rs 3642.40 crore in the year ended March 2025 as against Rs 3488.60 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales1018.00916.90 11 3642.403488.60 4 OPM %33.7534.56 -28.6029.08 - PBDT346.60320.10 8 1060.501057.80 0 PBT240.50209.00 15 627.90631.90 -1 NP183.30188.60 -3 496.20510.00 -3 Powered by Capital Market - Live

Syngene International has fixed 27 June 2025 as record date for payment of final dividend of Re.1.25/- per equity share of Rs. 10/- for the financial year 2024-25. Powered by Capital Market - Live

Syngene International will hold a meeting of the Board of Directors of the Company on 23 April 2025.Powered by Capital Market - Live

Peter Bains, with over 30 years of global experience in biopharmaceuticals, was appointed group CEO of Biocon in September 2023. Holding a bachelor's degree in science from the University of Sheffield, Bains previously served as CEO of Syngene International, where he led its public listing in 2015. He has also held leadership roles at Sosei Group and GlaxoSmithKline. Bains rejoined Biocon as an independent director in December 2022 before being appointed CEO. Syngene International is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. The company reported a 17.58% increase in consolidated net profit to Rs 131.1 crore in Q3 FY25 as compared with Rs 111.5 crore in Q3 FY24. Revenue from operations jumped 10.57% YoY to Rs 943.7 crore in Q3 FY25. Shares of Syngene International rose 0.95% to Rs 725 on the BSE.Powered by Capital Market - Live